Evident Vascular — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Evident Vascular is a venture-backed medical device startup founded in 2017, targeting the underpenetrated intravascular ultrasound (IVUS) market for peripheral arterial and venous disease. The company is developing an AI-enhanced IVUS platform designed to overcome the image quality and workflow limitations of current systems, thereby aiming to increase IVUS adoption in peripheral vascular interventions. Led by an experienced executive team with deep expertise in vascular devices and imaging, the company is positioned to capitalize on the growing prevalence of peripheral arterial disease and the projected increase in related interventions. Its initial focus is on peripheral applications, with plans to later expand into the coronary market.

Cardiovascular

Technology Platform

AI-enhanced intravascular ultrasound (IVUS) platform designed for superior image interpretation and improved clinical workflow in peripheral vascular interventions.

Opportunities

The growing prevalence of peripheral arterial disease and rising procedure volumes create a large and expanding addressable market.

Underutilization of current IVUS technology due to its limitations presents a clear penetration opportunity for a superior product.

Expansion from the initial peripheral focus into the coronary IVUS market offers a significant long-term growth pathway.

Risk Factors

The company faces high technical and regulatory execution risk as a pre-revenue startup with a single product in development.

It must compete against well-funded, entrenched incumbents with established customer relationships.

Achieving commercial adoption requires changing physician behavior and overcoming hospital procurement inertia, which is often slow and difficult.

Competitive Landscape

The intravascular ultrasound market is dominated by large, established medical device companies such as Philips and Boston Scientific, whose systems were originally developed for coronary applications. Competition is based on image quality, catheter profiles, workflow integration, and clinical data. Evident Vascular's strategy is to differentiate by specifically optimizing its AI-powered platform for peripheral vascular workflows and image interpretation, an area it views as neglected by the incumbents.

More companies in Diagnostics & Precision Medicine →More companies in United States →